{"paper_id":"f1538b41-ba63-4899-8772-e7490f47d2b6","body_text":"Abstract\nThe pathology of endometriosis is associated with various inflammatory cytokines, including IL-1β, and recent studies have shown that spheroid cell cultures can be used to investigate the mechanisms of endometriosis-associated inflammation and cell proliferation more effectively than that of monolayer cell cultures. However, the detailed role of the IL-1β signaling pathway in endometriotic stromal cells in spheroid cell cultures remains unclear. This study investigated the role of the IL-1β pathway in the pathogenesis of endometriosis in spheroid cell cultures derived from ovarian endometrioma stromal cells (OESCs) and normal endometrial stromal cells (NESCs). Specimens were collected from 22 patients with and 11 patients without endometriosis. IL-6/IL-8 protein production was evaluated by ELISA, gene expression by real-time PCR, cell proliferation by WST-8 assay, and RGS1 expression by immunohistochemical staining. Spheroid OESCs showed elevated IL-6/IL-8 production and increased expression of inflammation-related genes compared with monolayer cell cultures. IL-1β promoted the proliferation of spheroid OESCs and upregulated endometriosis-associated gene expression, but did not promote the proliferation of spheroid NESCs. Spheroid OESCs also showed increased levels of IL-1R1 and NLRP3 mRNA. IRAK4, TAK1, and RGS inhibitors suppressed cell proliferation and IL-6/IL-8 production in spheroid OESCs treated with IL-1β. Additionally, RGS1 was highly expressed in OESCs. The IL-1β pathway is crucial for OESCs proliferation and IL-6/IL-8 production in spheroid culture. Thus, RGS1, IRAK4, and TAK1 may serve as novel therapeutic targets for endometriosis.\nSimilar content being viewed by others\nData Availability\nAll data will be shared on reasonable request to the corresponding author.\nReferences\nBulun SE. Endometriosis. N Engl J Med. 2009;360:268–79. https://doi.org/10.1056/NEJMra0804690.\nBulun SE, Yilmaz BD, Sison C, Miyazaki K, Bernardi L, Liu S, et al. Endometriosis. Endocr Rev. 2019;40:1048–79. https://doi.org/10.1210/er.2018-00242.\nGiudice LC, Kao LC. Endometriosis. Lancet. 2004;364:1789–99. https://doi.org/10.1016/S0140-6736(04)17403-5.\nSampson JA. Metastatic or embolic endometriosis, due to the menstrual dissemination of endometrial tissue into the venous circulation. Am J Pathol. 1927;3:93.\nWu MY, Ho HN. The role of cytokines in endometriosis. Am J Reprod Immunol. 2003;49:285–96. https://doi.org/10.1034/j.1600-0897.2003.01207.x.\nHogg C, Horne AW, Greaves E. Endometriosis-associated macrophages: origin, phenotype, and function. Front Endocrinol (Lausanne). 2020;11:7. https://doi.org/10.3389/fendo.2020.00007.\nVoltolini Velho R, Halben N, Chekerov R, Keye J, Plendl J, Sehouli J, et al. Functional changes of immune cells: signal of immune tolerance of the ectopic lesions in endometriosis? Reprod Biomed Online. 2021;43:319–28. https://doi.org/10.1016/j.rbmo.2021.04.012.\nUrata Y, Koga K, Hirota Y, Akiyama I, Izumi G, Takamura M, et al. IL-1β increases expression of tryptophan 2,3-dioxygenase and stimulates tryptophan catabolism in endometrioma stromal cells. Am J Reprod Immunol. 2014;72:496–503. https://doi.org/10.1111/aji.12282.\nLebovic DI, Chao VA, Martini JF, Taylor RN. IL-1β induction of RANTES (regulated upon activation, normal T cell expressed and secreted) chemokine gene expression in endometriotic stromal cells depends on a nuclear factor-κB site in the proximal promoter. J Clin Endocrinol Metab. 2001;86:4759–64. https://doi.org/10.1210/jcem.86.10.7890.\nTakemura Y, Osuga Y, Yoshino O, Hasegawa A, Hirata T, Hirota Y, et al. Metformin suppresses interleukin (IL)-1β-induced IL-8 production, aromatase activation, and proliferation of endometriotic stromal cells. J Clin Endocrinol Metab. 2007;92:3213–8. https://doi.org/10.1210/jc.2006-2486.\nYoshino O, Izumi G, Shi J, Osuga Y, Hirota Y, Hirata T, et al. Activin-A is induced by interleukin-1β and tumor necrosis factor-α and enhances the mRNA expression of interleukin-6 and protease-activated receptor-2 and proliferation of stromal cells from endometrioma. Fertil Steril. 2011;96:118–21. https://doi.org/10.1016/j.fertnstert.2011.05.006.\nXu Z, Kombe Kombe AJ, Deng S, Zhang H, Wu S, Ruan J, et al. Nlrp inflammasomes in health and disease. Mol Biomed. 2024;5:14. https://doi.org/10.1186/s43556-024-00179-x.\nGarcía-Gómez E, Vázquez-Martínez ER, Reyes-Mayoral C, Cruz-Orozco OP, Camacho-Arroyo I, Cerbón M. Regulation of inflammation pathways and inflammasome by sex steroid hormones in endometriosis. Front Endocrinol (Lausanne). 2020;10:935. https://doi.org/10.3389/fendo.2019.00935.\nZhou F, Zhao F, Huang Q, Lin X, Zhang S, Dai Y. Nlrp3 activated macrophages promote endometrial stromal cells migration in endometriosis. J Reprod Immunol. 2022;152:103649. https://doi.org/10.1016/j.jri.2022.103649.\nBlevins HM, Xu Y, Biby S, Zhang S. The NLRP3 inflammasome pathway: a review of mechanisms and inhibitors for the treatment of inflammatory diseases. Front Aging Neurosci. 2022;14:879021. https://doi.org/10.3389/fnagi.2022.879021.\nKato T, Yasuda K, Matsushita K, Ishii KJ, Hirota S, Yoshimoto T, et al. Interleukin-1/−33 signaling pathways as therapeutic targets for endometriosis. Front Immunol. 2019;10:2021. https://doi.org/10.3389/fimmu.2019.02021.\nKaushal JB, Shukla V, Sankhwar P, Jha RK, Dwivedi A. Targeted inhibition of TAK1 abrogates TGFβ1 non-canonical signaling axis, NFκB/Smad7 inhibiting human endometriotic cells proliferation and inducing cell death involving autophagy. Cytokine. 2021;148:155700. https://doi.org/10.1016/j.cyto.2021.155700.\nŻuchowska A, Baranowska P, Flont M, Brzózka Z, Jastrzębska E. Review: 3D cell models for organ-on-a-chip applications. Anal Chim Acta. 2024;1301:342413. https://doi.org/10.1016/j.aca.2024.342413.\nYamanaka K, Xu B, Suganuma I, Kusuki I, Mita S, Shimizu Y, et al. Dienogest inhibits aromatase and cyclooxygenase-2 expression and prostaglandin E₂ production in human endometriotic stromal cells in spheroid culture. Fertil Steril. 2012;97:477–82. https://doi.org/10.1016/j.fertnstert.2011.11.005.\nSong Y, Burns GW, Joshi NR, Arora R, Kim JJ, Fazleabas AT. Spheroids as a model for endometriotic lesions. JCI Insight. 2023;8:e160815. https://doi.org/10.1172/jci.insight.160815.\nBrueggmann D, Templeman C, Starzinski-Powitz A, Rao NP, Gayther SA, Lawrenson K. Novel three-dimensional in vitro models of ovarian endometriosis. J Ovarian Res. 2014;7:17. https://doi.org/10.1186/1757-2215-7-17.\nDi Nicuolo F, Castellani R, De Cicco Nardone A, Barbaro G, Paciullo C, Pontecorvi A, et al. Alpha-lipoic acid plays a role in endometriosis: new evidence on inflammasome-mediated interleukin production, cellular adhesion and invasion. Molecules. 2021;26:288. https://doi.org/10.3390/molecules26020288.\nMinami T, Tsuzuki Y, Tanaka Y, Kitawaki J, Mori T. The Tpl2-MEK pathway plays a critical role in spheroid-cultured endometriotic stromal cells. Am J Reprod Immunol. 2023;89:e13689. https://doi.org/10.1111/aji.13689.\nMori T, Sawada M, Kuroboshi H, Tatsumi H, Katsuyama M, Iwasaku K, et al. Estrogen-related receptor α expression and function are associated with vascular endothelial growth factor in human cervical cancer. Int J Gynecol Cancer. 2011;21:609–15. https://doi.org/10.1097/IGC.0b013e3182017e9b.\nAhn SH, Khalaj K, Young SL, Lessey BA, Koti M, Tayade C. Immune-inflammation gene signatures in endometriosis patients. Fertil Steril. 2016;106:1420-1431.e7. https://doi.org/10.1016/j.fertnstert.2016.07.005.\nMiller JE, Monsanto SP, Ahn SH, Khalaj K, Fazleabas AT, Young SL, et al. Interleukin-33 modulates inflammation in endometriosis. Sci Rep. 2017;7:17903. https://doi.org/10.1038/s41598-017-18224-x.\nOno Y, Yoshino O, Hiraoka T, Akiyama I, Sato E, Ito M, et al. IL-33 exacerbates endometriotic lesions via polarizing peritoneal macrophages to M2 subtype. Reprod Sci. 2020;27:869–76. https://doi.org/10.1007/s43032-019-00090-9.\nBanu SK, Lee J, Speights VO, Starzinski-Powitz A, Arosh JA. Cyclooxygenase-2 regulates survival, migration, and invasion of human endometriotic cells through multiple mechanisms. Endocrinology. 2008;149:1180–9. https://doi.org/10.1210/en.2007-1168.\nCastle RD. IL-6 signaling pathway differentiation for endometriosis and inflammatory diseases. Explor Immunol. 2024;4(4):476–89. https://doi.org/10.37349/ei.2024.00153.\nLuk J, Seval Y, Kayisli UA, Ulukus M, Ulukus CE, Arici A. Regulation of interleukin-8 expression in human endometrial endothelial cells: a potential mechanism for the pathogenesis of endometriosis. J Clin Endocrinol Metab. 2005;90:1805–11. https://doi.org/10.1210/jc.2004-1813.\nKarin M, Delhase M. The IκB kinase (IKK) and NF-κB: key elements of proinflammatory signalling. Semin Immunol. 2000;12(1):85–98. https://doi.org/10.1006/smim.2000.0210.\nChung MS, Han SJ. Endometriosis-associated angiogenesis and anti-angiogenic therapy for endometriosis. Front Glob Womens Health. 2022;3:856316. https://doi.org/10.3389/fgwh.2022.856316.\nBroz P, Dixit VM. Inflammasomes: mechanism of assembly, regulation and signalling. Nat Rev Immunol. 2016;16:407–20. https://doi.org/10.1038/nri.2016.58.\nPatel J, Chuaiphichai S, Douglas G, Gorvin CM, Channon KM. Vascular wall regulator of G-protein signalling-1 (RGS-1) is required for angiotensin II-mediated blood pressure control. Vascul Pharmacol. 2018;108:15–22. https://doi.org/10.1016/j.vph.2018.04.002.\nXie Z, Chan EC, Druey KM. R4 regulator of G protein signaling (RGS) proteins in inflammation and immunity. AAPS J. 2016;18:294–304. https://doi.org/10.1208/s12248-015-9847-0.\nTan Y, Flynn WF, Sivajothi S, Luo D, Bozal SB, Davé M, et al. Single-cell analysis of endometriosis reveals a coordinated transcriptional programme driving immunotolerance and angiogenesis across eutopic and ectopic tissues. Nat Cell Biol. 2022;24:1306–18. https://doi.org/10.1038/s41556-022-00961-5.\nHayes MP, Bodle CR, Roman DL. Evaluation of the selectivity and cysteine dependence of inhibitors across the regulator of G protein-signaling family. Mol Pharmacol. 2018;93:25–35. https://doi.org/10.1124/mol.117.109843.\nTian X, Wang W, Zhang Q, Zhao L, Wei J, Xing H, et al. Hypoxia-inducible factor-1α enhances the malignant phenotype of multicellular spheroid HeLa cells in vitro. Oncol Lett. 2010;1:893–7. https://doi.org/10.3892/ol_00000159.\nTang Y-Y, Wang D-C, Wang Y-Q, Huang A-F, Xu W-D. Emerging role of hypoxia-inducible factor-1α in inflammatory autoimmune diseases: a comprehensive review. Front Immunol. 2022;13:1073971. https://doi.org/10.3389/fimmu.2022.1073971.\nYen BL, Hsieh C-C, Hsu P-J, Chang C-C, Wang L-T, Yen M-L. Three-dimensional spheroid culture of human mesenchymal stem cells: offering therapeutic advantages and in vitro glimpses of the in vivo state. Stem Cells Transl Med. 2023;12(5):235–44. https://doi.org/10.1093/stcltm/szad011.\nMatsuzaki S, Pouly JL, Canis M. Dose-dependent pro- or anti-fibrotic responses of endometriotic stromal cells to interleukin-1β and tumor necrosis factor α. Sci Rep. 2020;10:9467. https://doi.org/10.1038/s41598-020-66298-x.\nAkoum A, Al-Akoum M, Lemay A, Maheux R, Leboeuf M. Imbalance in the peritoneal levels of interleukin 1 and its decoy inhibitory receptor type II in endometriosis women with infertility and pelvic pain. Fertil Steril. 2008;89:1618–24. https://doi.org/10.1016/j.fertnstert.2007.06.019.\nWerdel R, Mabie A, Evans TL, Coté RD, Schlundt A, Doehrman P, et al. Serum levels of interleukins in endometriosis patients: a systematic review and meta-analysis. J Minim Invasive Gynecol. 2024;31:387-396.e11. https://doi.org/10.1016/j.jmig.2024.02.011.\nDinarello CA. A clinical perspective of IL-1β as the gatekeeper of inflammation. Eur J Immunol. 2011;41:1203–17. https://doi.org/10.1002/eji.201141550.\nHan SJ, Jung SY, Wu SP, Hawkins SM, Park MJ, Kyo S, et al. Estrogen receptor β modulates apoptosis complexes and the inflammasome to drive the pathogenesis of endometriosis. Cell. 2015;163:960–74. https://doi.org/10.1016/j.cell.2015.10.034.\nMurakami M, Osuka S, Muraoka A, Hayashi S, Bayasula KY, Kasahara Y, et al. Effectiveness of NLRP3 inhibitor as a non-hormonal treatment for ovarian endometriosis. Reprod Biol Endocrinol. 2022;20:58. https://doi.org/10.1186/s12958-022-00924-3.\nZarrin AA, Bao K, Lupardus P, Vucic D. Kinase inhibition in autoimmunity and inflammation. Nat Rev Drug Discov. 2021;20:39–63. https://doi.org/10.1038/s41573-020-0082-8.\nHu X, Tang J, Zeng G, Hu X, Bao P, Wu J, et al. RGS1 silencing inhibits the inflammatory response and angiogenesis in rheumatoid arthritis rats through the inactivation of toll-like receptor signaling pathway. J Cell Physiol. 2019;234:20432–42. https://doi.org/10.1002/jcp.28645.\nGu J, Wei YL, Wei JC, Huang F, Jan MS, Centola M, et al. Identification of RGS1 as a candidate biomarker for undifferentiated spondylarthritis by genome-wide expression profiling and real-time polymerase chain reaction. Arthritis Rheum. 2009;60:3269–79. https://doi.org/10.1002/art.24968.\nAcknowledgements\nWe thank Ms. Makoto Kazui and Ms. Naoko Matsunaga for their technical support, and Dr. Gerald E. Smyth, Nippon Shinyaku Co., Ltd., for English language revision. This study was funded in part by the Ministry of Education, Culture, Sports, Science and Technology (Japan) through Grants-in-Aid for Scientific Research (21K09523, 23K15819).\nAuthor information\nAuthors and Affiliations\nContributions\n1. Yota Tsuzuki: Conceptualization (equal); Writing – Original Draft Preparation (lead); Investigation (lead).\n2. Yosuke Tarumi: Project Administration (supporting); Resources (equal).\n3. Toshiyuki Minami: Conceptualization (equal); Writing – Original Draft Preparation (supporting).\n4. Fumitake Ito: Resources (equal).\n5. Koki Shimura: Resources (equal).\n6. Akihisa Katayama: Resources (equal).\n7. Yuko Izumi: Resources (equal).\n8. Jo Kitawaki: Project Administration (equal).\n9. Taisuke Mori: Project Administration (lead); Supervision (lead).\nCorresponding author\nEthics declarations\nEthics Approval\nThis study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Institutional Review Board of the Kyoto Prefectural University of Medicine (approval no., ERB-C-2410).\nConsent to Participate\nAll participants provided written informed consent before participation.\nConsent to Publication\nAll agreed to publish this article.\nCompeting interests\nYota Tsuzuki and Toshiyuki Minami are employed by Nippon Shinyaku Co., Ltd. The remaining authors declare that they have nothing to disclose.\nAdditional information\nPublisher's Note\nSpringer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.\nRights and permissions\nSpringer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.\nAbout this article\nCite this article\nTsuzuki, Y., Tarumi, Y., Minami, T. et al. Proposed Role of RGS1 in Modulating IL-1β-IL-1R1-IRAK4-TAK1 Signaling in Endometriotic Stromal Cells. Reprod. Sci. 33, 346–357 (2026). https://doi.org/10.1007/s43032-025-02014-2\nReceived:\nAccepted:\nPublished:\nVersion of record:\nIssue date:\nDOI: https://doi.org/10.1007/s43032-025-02014-2","source_license":"public-domain-us","license_restricted":false}